Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 4Recurrence 1Aumolertinib 1

Interventions

Cyclophosphamide 6fludarabine 5toripalimab 3Etoposide 3Drug Therapy 3zimberelimab 2tislelizumab 2sintilimab 2glumetinib 2cemiplimab 2Vincristine 2Temozolomide 2Platinum 2Paclitaxel 2Injections 2Immunotherapy, Adoptive 2Immune Checkpoint Inhibitors 2Hepatectomy 2Gemcitabine 2Docetaxel 2Carboplatin 2Capecitabine 2Bevacizumab 2venetoclax 1relmacabtagene autoleucel 1pomalidomide 1pirtobrutinib 1osimertinib 1lenvatinib 1irinotecan sucrosofate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Recurrence × aumolertinib × Clear all
NCT05503888 2022-08-17

Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 1/2 Not yet recruiting
160 enrolled

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡